BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 28249612)

  • 1. Do selective radiation dose escalation and tumour hypoxia status impact the loco-regional tumour control after radio-chemotherapy of head & neck tumours? The ESCALOX protocol.
    Pigorsch SU; Wilkens JJ; Kampfer S; Kehl V; Hapfelmeier A; Schläger C; Bier H; Schwaiger M; Combs SE
    Radiat Oncol; 2017 Mar; 12(1):45. PubMed ID: 28249612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [SIB-IMRT radiotherapy given concomitantly with cisplatin for locally advanced squamous cell head and neck cancer (SCHNC). Evaluation of the early results and toxicity].
    Kiprian D; Jarząbski A; Pawłowska B; Michalski W; Kawecki A
    Otolaryngol Pol; 2011 Sep; 65(5 Suppl):117-25. PubMed ID: 22000261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Locally advanced head and neck cancer treated with accelerated radiotherapy, the hypoxic modifier nimorazole and weekly cisplatin. Results from the DAHANCA 18 phase II study.
    Bentzen J; Toustrup K; Eriksen JG; Primdahl H; Andersen LJ; Overgaard J
    Acta Oncol; 2015 Jul; 54(7):1001-7. PubMed ID: 25629651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tirapazamine, cisplatin, and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck (TROG 02.02, HeadSTART): a phase III trial of the Trans-Tasman Radiation Oncology Group.
    Rischin D; Peters LJ; O'Sullivan B; Giralt J; Fisher R; Yuen K; Trotti A; Bernier J; Bourhis J; Ringash J; Henke M; Kenny L
    J Clin Oncol; 2010 Jun; 28(18):2989-95. PubMed ID: 20479425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer.
    Heukelom J; Hamming O; Bartelink H; Hoebers F; Giralt J; Herlestam T; Verheij M; van den Brekel M; Vogel W; Slevin N; Deutsch E; Sonke JJ; Lambin P; Rasch C
    BMC Cancer; 2013 Feb; 13():84. PubMed ID: 23433435
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensity-modulated radiation treatment for head-and-neck squamous cell carcinoma--the University of Iowa experience.
    Yao M; Dornfeld KJ; Buatti JM; Skwarchuk M; Tan H; Nguyen T; Wacha J; Bayouth JE; Funk GF; Smith RB; Graham SM; Chang K; Hoffman HT
    Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):410-21. PubMed ID: 16168834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Geometric analysis of loco-regional recurrences in relation to pre-treatment hypoxia in patients with head and neck cancer.
    Boeke S; Thorwarth D; Mönnich D; Pfannenberg C; Reischl G; La Fougère C; Nikolaou K; Mauz PS; Paulsen F; Zips D; Welz S
    Acta Oncol; 2017 Nov; 56(11):1571-1576. PubMed ID: 28891398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma.
    van den Bosch S; Dijkema T; Kunze-Busch MC; Terhaard CH; Raaijmakers CP; Doornaert PA; Hoebers FJ; Vergeer MR; Kreike B; Wijers OB; Oyen WJ; Kaanders JH
    BMC Cancer; 2017 Mar; 17(1):208. PubMed ID: 28327089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of dynamic hypoxia PET in head and neck cancer: Results from a planned interim analysis of a randomized phase II hypoxia-image guided dose escalation trial.
    Welz S; Mönnich D; Pfannenberg C; Nikolaou K; Reimold M; La Fougère C; Reischl G; Mauz PS; Paulsen F; Alber M; Belka C; Zips D; Thorwarth D
    Radiother Oncol; 2017 Sep; 124(3):526-532. PubMed ID: 28434798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer.
    Prosnitz RG; Yao B; Farrell CL; Clough R; Brizel DM
    Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1087-95. PubMed ID: 15752888
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panitumumab plus radiotherapy versus chemoradiotherapy in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-2): a randomised, controlled, open-label phase 2 trial.
    Giralt J; Trigo J; Nuyts S; Ozsahin M; Skladowski K; Hatoum G; Daisne JF; Yunes Ancona AC; Cmelak A; Mesía R; Zhang A; Oliner KS; VanderWalde A
    Lancet Oncol; 2015 Feb; 16(2):221-32. PubMed ID: 25596659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMRT: preliminary results in a series of advanced head-and-neck cancer patients.
    Vila Capel A; Vilar Palop J; Pedro Olivé A; Sanchez-Reyes Fernandez A; Vayreda Ribera J; Julià Sanahuja JC; Pérez de Olaguer Agustín J; Artola Codina N; Moya Cascant LM; Rubio Calatayud E; Carrera Domenech G
    Clin Transl Oncol; 2013 Mar; 15(3):233-42. PubMed ID: 22855193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoradiotherapy with or without panitumumab in patients with unresected, locally advanced squamous-cell carcinoma of the head and neck (CONCERT-1): a randomised, controlled, open-label phase 2 trial.
    Mesía R; Henke M; Fortin A; Minn H; Yunes Ancona AC; Cmelak A; Markowitz AB; Hotte SJ; Singh S; Chan AT; Merlano MC; Skladowski K; Zhang A; Oliner KS; VanderWalde A; Giralt J
    Lancet Oncol; 2015 Feb; 16(2):208-20. PubMed ID: 25596660
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Concomitant cisplatin, paclitaxel, and hyperfractionated radiotherapy in locally advanced head and neck cancer: comparison of two different schedules.
    Moreno-Jiménez M; Valero J; López-Picazo JM; Arbea L; Aristu J; Cambeiro M; Alcalde J; Martínez-Monge R
    Am J Clin Oncol; 2010 Apr; 33(2):137-43. PubMed ID: 19786847
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A dose escalation study with intensity modulated radiation therapy (IMRT) in T2N0, T2N1, T3N0 squamous cell carcinomas (SCC) of the oropharynx, larynx and hypopharynx using a simultaneous integrated boost (SIB) approach.
    Leclerc M; Maingon P; Hamoir M; Dalban C; Calais G; Nuyts S; Serre A; Grégoire V
    Radiother Oncol; 2013 Mar; 106(3):333-40. PubMed ID: 23541643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Preliminary results of Radiation Therapy Oncology Group 97-03: a randomized phase ii trial of concurrent radiation and chemotherapy for advanced squamous cell carcinomas of the head and neck.
    Garden AS; Harris J; Vokes EE; Forastiere AA; Ridge JA; Jones C; Horwitz EM; Glisson BS; Nabell L; Cooper JS; Demas W; Gore E
    J Clin Oncol; 2004 Jul; 22(14):2856-64. PubMed ID: 15254053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation treatment interruptions greater than one week and low hemoglobin levels (12 g/dL) are predictors of local regional failure after definitive concurrent chemotherapy and intensity-modulated radiation therapy for squamous cell carcinoma of the head and neck.
    McCloskey SA; Jaggernauth W; Rigual NR; Hicks WL; Popat SR; Sullivan M; Mashtare TL; Khan MK; Loree TR; Singh AK
    Am J Clin Oncol; 2009 Dec; 32(6):587-91. PubMed ID: 19581794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concurrent cisplatin and dose escalation with intensity-modulated radiotherapy (IMRT) versus conventional radiotherapy for locally advanced head and neck squamous cell carcinomas (HNSCC): GORTEC 2004-01 randomized phase III trial.
    Tao Y; Auperin A; Blanchard P; Alfonsi M; Sun XS; Rives M; Pointreau Y; Castelli J; Graff P; Wong Hee Kam S; Thariat J; Veresezan O; Heymann S; Renard-Oldrini S; Lafond C; Cornely A; Casiraghi O; Boisselier P; Lapeyre M; Biau J; Bourhis J
    Radiother Oncol; 2020 Sep; 150():18-25. PubMed ID: 32417348
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.